Compare Stocks: ANAB, CGON, SRRK, and MIRM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$57.64 +1.7%	$58.53	$11.40 ▼ $72.36	$1.71B	0.72	719,277 shs	149,279 shs
CGON CG Oncology	$79.26 +2.1%	$70.91	$25.25 ▼ $80.97	$7.03B	0.23	1.13 million shs	213,561 shs
MIRM Mirum Pharmaceuticals	$95.98 -1.1%	$111.26	$63.23 ▼ $130.00	$6.23B	0.52	877,821 shs	277,410 shs
SRRK Scholar Rock	$55.90 +1.2%	$51.61	$27.07 ▼ $58.49	$6.81B	0.69	1.33 million shs	460,658 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-4.34%	+1.20%	+5.45%	-5.06%	+181.34%
CGON CG Oncology	-3.81%	+3.88%	+8.21%	+20.79%	+204.00%
MIRM Mirum Pharmaceuticals	-5.06%	-1.72%	-17.07%	-1.57%	+45.51%
SRRK Scholar Rock	-2.23%	+4.13%	+8.59%	+14.79%	+60.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$57.64 +1.7%	$58.53	$11.40 ▼ $72.36	$1.71B	0.72	719,277 shs	149,279 shs
CGON CG Oncology	$79.26 +2.1%	$70.91	$25.25 ▼ $80.97	$7.03B	0.23	1.13 million shs	213,561 shs
MIRM Mirum Pharmaceuticals	$95.98 -1.1%	$111.26	$63.23 ▼ $130.00	$6.23B	0.52	877,821 shs	277,410 shs
SRRK Scholar Rock	$55.90 +1.2%	$51.61	$27.07 ▼ $58.49	$6.81B	0.69	1.33 million shs	460,658 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-4.34%	+1.20%	+5.45%	-5.06%	+181.34%
CGON CG Oncology	-3.81%	+3.88%	+8.21%	+20.79%	+204.00%
MIRM Mirum Pharmaceuticals	-5.06%	-1.72%	-17.07%	-1.57%	+45.51%
SRRK Scholar Rock	-2.23%	+4.13%	+8.59%	+14.79%	+60.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.67	Moderate Buy	$82.00	42.26% Upside
CGON CG Oncology	2.71	Moderate Buy	$83.18	4.95% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$137.33	43.09% Upside
SRRK Scholar Rock	3.13	Buy	$58.31	4.31% Upside

Current Analyst Ratings Breakdown

Latest ANAB, CGON, SRRK, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/13/2026	SRRK Scholar Rock	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$56.00 ➝ $63.00
8/10/2026	SRRK Scholar Rock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
8/10/2026	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$58.00
8/7/2026	ANAB AnaptysBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/7/2026	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$76.00
8/7/2026	SRRK Scholar Rock	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$58.00 ➝ $60.00
8/7/2026	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$81.00 ➝ $79.00
8/7/2026	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $85.00
8/7/2026	CGON CG Oncology	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$82.00 ➝ $85.00
8/6/2026	MIRM Mirum Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)

(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$234.60M	7.28	N/A	N/A	$1.34 per share	43.01
CGON CG Oncology	$6.23M	1,128.07	N/A	N/A	$11.61 per share	6.83
MIRM Mirum Pharmaceuticals	$618.07M	10.08	$0.05 per share	2,005.53	($0.16) per share	-599.88
SRRK Scholar Rock	N/A	N/A	N/A	N/A	$2.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$13.23M	-$1.08	N/A	17.74	N/A	-11.53%	N/A	-7.75%	N/A
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	N/A
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
SRRK Scholar Rock	-$377.94M	-$3.45	N/A	N/A	N/A	N/A	-160.19%	-87.18%	N/A

Latest ANAB, CGON, SRRK, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/6/2026	Q2 2026	SRRK Scholar Rock	-$0.8405	-$0.84	+$0.0005	-$0.84	$3.33 million	N/A
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	7.58	7.58
CGON CG Oncology	N/A	22.22	22.20
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
SRRK Scholar Rock	0.77	7.02	7.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
CGON CG Oncology	26.56%
MIRM Mirum Pharmaceuticals	N/A
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	31.50%
CGON CG Oncology	4.80%
MIRM Mirum Pharmaceuticals	8.32%
SRRK Scholar Rock	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	29.61 million	20.28 million	Optionable
CGON CG Oncology	61	88.64 million	84.39 million	Optionable
MIRM Mirum Pharmaceuticals	140	64.93 million	59.53 million	Optionable
SRRK Scholar Rock	140	121.79 million	109.24 million	Optionable

ANAB, CGON, SRRK, and MIRM Headlines

Recent News About These Companies

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

4 hours ago | businesswire.com

Eagle Health Investments LP Invests $30.54 Million in Scholar Rock Holding Corporation $SRRK

August 20 at 4:23 AM | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Consensus Rating of "Buy" by Brokerages

August 20 at 2:14 AM | americanbankingnews.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of "Buy" from Brokerages

August 20 at 2:13 AM | marketbeat.com

Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab

August 17, 2026 | marketbeat.com

Canaccord Genuity Keeps Their Buy Rating on Scholar Rock Holding (SRRK)

August 16, 2026 | theglobeandmail.com

Is Scholar Rock Holding Corporation (SRRK) Better Positioned than Novo Nordisk A/S (NVO) After Recent Setbacks?

August 16, 2026 | finance.yahoo.com

Is Scholar Rock Holding Corporation (SRRK) Better Positioned than Novo Nordisk A/S (NVO) After Recent Setbacks?

August 14, 2026 | insidermonkey.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 14, 2026 | businesswire.com

Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

August 13, 2026 | marketbeat.com

Scholar Rock (SRRK) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Q3 EPS Estimates for Scholar Rock Decreased by HC Wainwright

August 13, 2026 | americanbankingnews.com

Scholar Rock (NASDAQ:SRRK) Earns "Outperform" Rating from Wedbush

August 12, 2026 | americanbankingnews.com

Q3 EPS Estimates for Scholar Rock Cut by HC Wainwright

August 11, 2026 | marketbeat.com

Bank of America Corp DE Buys 286,126 Shares of Scholar Rock Holding Corporation $SRRK

August 11, 2026 | marketbeat.com

Scholar Rock's (SRRK) Outperform Rating Reiterated at Wedbush

August 10, 2026 | marketbeat.com

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval ...

August 8, 2026 | uk.finance.yahoo.com

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

August 7, 2026 | reuters.com

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

August 7, 2026 | businesswire.com

Scholar Rock Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Releases Earnings Results, Meets Estimates

August 6, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB, CGON, SRRK, and MIRM Company Descriptions

AnaptysBio NASDAQ:ANAB

$57.60 +0.91 (+1.61%)

As of 01:36 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

CG Oncology NASDAQ:CGON

$79.07 +1.46 (+1.88%)

As of 01:39 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$95.71 -1.36 (-1.40%)

As of 01:39 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Scholar Rock NASDAQ:SRRK

$55.82 +0.57 (+1.03%)

As of 01:39 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANAB, CGON, SRRK, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANAB, CGON, SRRK, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANAB, CGON, SRRK, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB, CGON, SRRK, and MIRM Company Descriptions

AnaptysBio NASDAQ:ANAB

CG Oncology NASDAQ:CGON

Mirum Pharmaceuticals NASDAQ:MIRM

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANAB, CGON, SRRK, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANAB, CGON, SRRK, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANAB, CGON, SRRK, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB, CGON, SRRK, and MIRM Company Descriptions

AnaptysBio NASDAQ:ANAB

CG Oncology NASDAQ:CGON

Mirum Pharmaceuticals NASDAQ:MIRM

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools